This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vikhanskaya, F. Articles by Broggini, M. Search for Related Content PubMed PubMed Citation Articles by Vikhanskaya, F. Articles by Broggini, M.

Cooperation between p53 and hMLH1 in a Human Colocarcinoma Cell Line in Response to DNA Damage¹

Molecular Pharmacology Unit, Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri" via Eritrea, 62 20157 Milan, Italy [F. V., G. C., M. D., M. B.], and Department of Experimental Oncology, Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy [M. V., S. P.]

We have studied the possible interactions between the mismatch repair system and p53 in a human colon cancer cell line, HCT-116 (known to have a homozygous mutation in mismatch repair gene hMLH1 on chromosome 3) and in a clone obtained after insertion of a single copy of chromosome 3 (HCT-116+ ch3).

Loss of DNA mismatch repair activity resulted in resistance to cisplatin (DDP). p53 accumulated differently in these cell lines after treatment with DDP. Initially at similar high levels after DDP treatment, p53 maintained the increase in HCT-116 cells, even 72–96 h after drug exposure, whereas HCT-116+ch3 mismatch-proficient cell line p53 declined to basal levels after 48 h. The higher levels of p53 in mismatch-deficient HCT-116 cells were accompanied by increased transcriptional activity as assessed by the gel-retardation assay and by activation of a promoter containing a p53 DNA binding site.

To better understand the role of p53, if any, in cell sensitivity to DDP, we disrupted p53 in both cell lines by stable transfection with the human papillomavirus type 16 E6 gene. HCT-116/E6 cells were more sensitive to DDP than the parental cell line, whereas HCT-116+ch3/E6 were fairly similar to HCT-116+ch3 with normal p53 function.

Although in our system the transfer of the entire chromosome 3 was used (thus not excluding a possible role of other genes localized on this chromosome), our data indicate that p53 can cooperate with the mismatch repair system. In fact, the lack of hLMH1, at least in these cells, enhances the role of p53 in protecting the cells from DDP-induced DNA damage.

This article has been cited by other articles:

				X. Lin and S. B. Howell DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance Mol. Cancer Ther., May 1, 2006; 5(5): 1239 - 1247. [Abstract] [Full Text] [PDF]

				S Kruger, A Bier, C Engel, E Mangold, C Pagenstecher, M von Knebel Doeberitz, E Holinski-Feder, G Moeslein, K Schulmann, J Plaschke, et al. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC) J. Med. Genet., October 1, 2005; 42(10): 769 - 773. [Abstract] [Full Text] [PDF]

				J. Chen and I. Sadowski Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements PNAS, March 29, 2005; 102(13): 4813 - 4818. [Abstract] [Full Text] [PDF]

				T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea Clin. Cancer Res., February 15, 2005; 11(4): 1539 - 1544. [Abstract] [Full Text] [PDF]

				K. Kishi, Y. Doki, M. Yano, T. Yasuda, Y. Fujiwara, S. Takiguchi, S. Kim, I. Higuchi, and M. Monden Reduced MLH1 Expression after Chemotherapy Is an Indicator for Poor Prognosis in Esophageal Cancers Clin. Cancer Res., October 1, 2003; 9(12): 4368 - 4375. [Abstract] [Full Text] [PDF]

				M. Meyers, M. W. Wagner, H.-S. Hwang, T. J. Kinsella, and D. A. Boothman Role of the hMLH1 DNA Mismatch Repair Protein in Fluoropyrimidine-mediated Cell Death and Cell Cycle Responses Cancer Res., July 1, 2001; 61(13): 5193 - 5201. [Abstract] [Full Text] [PDF]

				X. Lu, J. Errington, N. J. Curtin, J. Lunec, and D. R. Newell The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs Clin. Cancer Res., July 1, 2001; 7(7): 2114 - 2123. [Abstract] [Full Text] [PDF]

				X. Lin, K. Ramamurthi, M. Mishima, A. Kondo, and S. B. Howell p53 Interacts with the DNA Mismatch Repair System to Modulate the Cytotoxicity and Mutagenicity of Hydrogen Peroxide Mol. Pharmacol., April 13, 2001; 58(6): 1222 - 1229. [Abstract] [Full Text]

				R. A. Hardman, C. A. Afshari, and J. C. Barrett Involvement of Mammalian MLH1 in the Apoptotic Response to Peroxide-induced Oxidative Stress Cancer Res., February 1, 2001; 61(4): 1392 - 1397. [Abstract] [Full Text]

				X. Lin, K. Ramamurthi, M. Mishima, A. Kondo, R. D. Christen, and S. B. Howell p53 Modulates the Effect of Loss of DNA Mismatch Repair on the Sensitivity of Human Colon Cancer Cells to the Cytotoxic and Mutagenic Effects of Cisplatin Cancer Res., February 1, 2001; 61(4): 1508 - 1516. [Abstract] [Full Text]

				G. Damia, Y. Sanchez, E. Erba, and M. Broggini DNA Damage Induces p53-dependent Down-regulation of hCHK1 J. Biol. Chem., March 30, 2001; 276(14): 10641 - 10645. [Abstract] [Full Text] [PDF]